AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|
27.6 C
New York
Sunday, June 28, 2026

Tag: novel

newssourceFORcompanyinformationcontent1releasesmarket

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug developmentAppointments...

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June...

Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new...

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

They’re Baaaa-ck: SDGE Deploys 300 Goats in San Diego, Launches Instagram to Spotlight Wildfire Prevention Measures

SAN DIEGO, June 17, 2025 /PRNewswire/ -- San Diego Gas & Electric (SDGE) is combining hooves-on-the-ground innovation with digital storytelling by launching a new...

Chronic Hepatitis B Market–The US to Have the Lion’s Share Among the 7MM, Predicts DelveInsight

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...

Applied Therapeutics Announces Key Leadership Appointments

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated...

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2023 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Calviri Publishes Results Demonstrating Sensitive Detection of Stage 1 Tumors in Dogs

PHOENIX, June 17, 2025 /PRNewswire/ -- Calviri, Inc, a company focused on ending cancer in dogs and people, announces the publication of High-sensitivity multicancer...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNovel

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers